daunorubicin + cytarabine + azacitidine

This is a combination of three antineoplastic agents used in the treatment of acute myeloid leukemia (AML). Daunorubicin is an anthracycline that forms complexes with DNA, inhibits topoisomerase II activity, inhibits DNA polymerase activity, affects regulation of gene expression, and produces DNA-damaging free radicals. Cytarabine (ara-C) is a cell cycle-specific agent that affects cells during the S-phase of cell division by inhibiting DNA polymerase. Azacitidine is a hypomethylating agent that may enhance the efficacy of the other components. While daunorubicin and cytarabine are commonly used together (including in the liposomal formulation Vyxeos), the addition of azacitidine represents an approach to potentially improve outcomes in AML treatment.

Other names

daunorubicin + ara-cytarabine + azacitidine